HM13

Minor histocompatibility antigen H13 · Q8TCT9 · HM13 on Sugi Atlas →

0 patent compounds predicted against HM13, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to HM13 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence PHASE3COMPLETED
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit PHASE2/PHASE3WITHDRAWN
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes PHASE3COMPLETED
A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP) PHASE3COMPLETED
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus PHASE2COMPLETED
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus PHASE2COMPLETED
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma PHASE1/PHASE2COMPLETED
Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis PHASE2RECRUITING
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC PHASE2RECRUITING
Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139 PHASE2COMPLETED
Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients PHASE1/PHASE2WITHDRAWN
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma PHASE2COMPLETED
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis PHASE1/PHASE2WITHDRAWN
Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome PHASE2WITHDRAWN
Evaluation of the Safety, Tolerability and Pharmacokinetics of HY8931 in Healthy Adult Participants PHASE1RECRUITING
0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck PHASE1COMPLETED
A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor PHASE1WITHDRAWN
Pilot Study of Neoantigen Peptides for the Treatment of Neoplasms EARLY_PHASE1COMPLETED
Effects of Vitamin D Replacement on Hormones Regulating Iron Metabolism in Individuals With Chronic Kidney Disease EARLY_PHASE1COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C nanCOMPLETED
Identification of Immunogenic Neo-epitopes for the Development of Personalised Pancreatic Cancer Vaccines nanCOMPLETED
Analysis by Clinical Mass Spectrometry of Bloodstains nanCOMPLETED
Circulating Markers for Ischemic Heart Disease nanRECRUITING
Role of Interleukin-13 Pathways on Pain and Itch Sensitivity nanRECRUITING
Genes-in-Action - Hepcidin Regulation of Iron Supplementation nanCOMPLETED
Patient's Derived Organoids for Drug Screening in Glioblastoma nanNOT_YET_RECRUITING
Presepsin:Gelsolin Ratio in Sepsis-related Organ Dysfunction nanCOMPLETED
Relative Contribution of Brain Insulin Action for Postprandial Metabolism nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a HM13 binder may also engage these)

ProteinNameSimilarity
Q9D8V0 1.000 Q9D8V0 →
Q6ZGL9 0.997 Q6ZGL9 →
B9FJ61 0.996 B9FJ61 →
O81062 0.991 O81062 →
Q9UTA3 0.986 Q9UTA3 →
P49049 0.985 P49049 →
Q8W469 0.985 Q8W469 →
Q0DWA9 0.985 Q0DWA9 →
Q5Z413 0.984 Q5Z413 →
Q0WMJ8 0.984 Q0WMJ8 →
Q5AXD1 0.981 Q5AXD1 →
Q4W9R7 0.981 Q4W9R7 →
Q5N808 0.981 Q5N808 →
Q6C7Q6 0.980 Q6C7Q6 →
Q2U0S9 0.980 Q2U0S9 →
P31382 0.979 P31382 →
O59712 0.979 O59712 →
Q9P381 0.979 Q9P381 →
O04928 0.979 O04928 →
P53439 0.979 P53439 →
Q9MA44 0.979 Q9MA44 →
Q6CAW6 0.979 Q6CAW6 →
Q28E01 0.979 Q28E01 →
Q4WJJ9 0.979 Q4WJJ9 →
Q9SJT7 0.978 Q9SJT7 →
Q6C0Z3 0.978 Q6C0Z3 →
Q9P7P0 0.977 Q9P7P0 →
P56079 0.977 P56079 →
O49639 0.977 O49639 →
C5FZ62 0.977 C5FZ62 →